ImmuCell Unveils Impressive Sales Results for Recent Quarter
ImmuCell Corporation (Nasdaq: ICCC) has recently shared its preliminary, unaudited sales results for the third quarter of 2024, concluding on September 30, 2024. As a notable player in the animal health sector, ImmuCell is dedicated to creating scientifically validated products aimed at improving the health and productivity of dairy and beef cattle.
Sales Performance Overview
During the three-month period ending September 30, 2024, ImmuCell reported total sales of $6.0 million, demonstrating a robust increase compared to the $5.4 million recorded for the same period the previous year. This signifies a remarkable increase of $615,000, which translates to an 11% growth rate.
Nine-Month and Annual Performance Metrics
ImmuCell's performance over nine months is even more impressive, with sales soaring to $18.7 million from $12.4 million in the prior year, marking an extraordinary 51% increase. The twelve-month overview highlights total sales reaching $23.8 million, significantly up from $16.3 million, which is a commendable 46% uplift. The numbers strongly indicate that ImmuCell's products are resonating well in the market.
Production Capacity and Order Backlog
The company reported that production output during the respective periods was approximately 73%, 81%, and 77% of its estimated full production capacity, which stands at roughly $30 million annually. Furthermore, as of the end of September 2024, ImmuCell had an order backlog amounting to approximately $7.3 million, suggesting a heightened demand as retailers aim to replenish their stocks and as clients place orders ahead of the upcoming calving season.
Commitment to Innovation
A focal point of ImmuCell's growth strategy is its ongoing efforts towards gaining FDA approval for Re-Tain, a breakthrough treatment designed for subclinical mastitis in dairy cows. Michael F. Brigham, the President and CEO, remarked on the importance of this product, emphasizing their commitment to navigating the approval process efficiently. The company plans to file a Non-Administrative NADA submission after addressing feedback from previous communications with the FDA.
Future Plans and Continued Updates
To maintain transparency, ImmuCell has expressed its intention to keep stakeholders informed with regular updates regarding sales and product developments. They have consistently provided early insights into quarterly results and plan to continue this practice going forward.
Upcoming Conference Call Announcement
On November 14, 2024, at 9:00 AM ET, ImmuCell will host a conference call to discuss the unaudited financial results for Q3, aiding investors and stakeholders in understanding the financial landscape of the company more clearly.
About ImmuCell Corporation
ImmuCell Corporation's mission is rooted in improving animal health through innovative solutions, specifically designed for cattle. Their flagship product, First Defense, is recognized for providing Immediate Immunity™ to newborn calves. Furthermore, the upcoming Re-Tain product positions them as leaders in the endeavor to reduce reliance on traditional antibiotics in livestock, highlighting their role in promoting healthier farming practices.
Frequently Asked Questions
What are the sales figures for Q3 2024?
ImmuCell reported sales of $6.0 million for Q3 2024, up from $5.4 million in the previous year, indicating an 11% increase.
How does the nine-month performance compare to last year?
For the nine-month period, sales surged to $18.7 million, compared to $12.4 million last year, representing a remarkable 51% growth.
What is the current order backlog for ImmuCell?
The current backlog of orders stands at approximately $7.3 million, reflecting strong demand in the market.
What is ImmuCell's strategy for gaining FDA approval?
ImmuCell is focusing on completing necessary submissions and addressing FDA feedback for the Re-Tain product to expedite the approval process.
When is the next conference call?
The next conference call is scheduled for November 14, 2024, at 9:00 AM ET, to discuss the financial results with stakeholders.
